← Back to headlines
Immunity Bio Addresses FDA Concerns Regarding Anktiva Marketing
Immunity Bio has issued a response to the Food and Drug Administration's concerns regarding the marketing materials for its product, Anktiva.
6 Apr, 12:36 — 6 Apr, 12:36
Sources
Showing 1 of 1 sources
Related Stories
Amazon's First Customer Receipt Goes Viral, Bezos and Musk React
just now
Four Arrested for Selling P102 Million in Counterfeit Anti-Cancer Medicine in Makati
just now
Philippines receives diesel shipment from Malaysia
just now
Bulgaria Issues 12,000 Permits for Foreign Tourism Workers in Three Months
15m ago